Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Gyre Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Gyre Therapeutics, Inc.’s stock price such as:

• Gyre Therapeutics, Inc.’s current stock price and volume
• Why Gyre Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for GYRE from analysts
• GYRE’s stock price momentum as measured by its relative strength

About Gyre Therapeutics, Inc. (GYRE)

Before we jump into Gyre Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY, under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573 is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

Want to learn more about Gyre Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Gyre Therapeutics, Inc..

Gyre Therapeutics, Inc.’s Stock Price as of Market Close

As of June 03, 2026, 12:59 PM, CST, Gyre Therapeutics, Inc.’s stock price was $5.640.

Gyre Therapeutics, Inc. is up 1.44% from its previous closing price of $5.560.

During the last market session, Gyre Therapeutics, Inc.’s stock traded between $5.500 and $5.660. Currently, there are approximately 91.32 million shares outstanding for Gyre Therapeutics, Inc..

Gyre Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Gyre Therapeutics, Inc. Stock Price History

Gyre Therapeutics, Inc.’s (GYRE) price is currently down 4.57% so far this month.

During the month of June, Gyre Therapeutics, Inc.’s stock price has reached a high of $6.020 and a low of $5.440.

Over the last year, Gyre Therapeutics, Inc. has hit prices as high as $9.420 and as low as $5.440. Year to date, Gyre Therapeutics, Inc.’s stock is down 20.11%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Gyre Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 02, 2026, there was 1 analyst who downgraded Gyre Therapeutics, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Gyre Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Gyre Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Gyre Therapeutics, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Gyre Therapeutics, Inc. (GYRE) by visiting AAII Stock Evaluator.

Relative Price Strength of Gyre Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 02, 2026, Gyre Therapeutics, Inc. has a weighted four-quarter relative price strength of -17.00%, which translates to a Momentum Score of 14 and is considered to be Very Weak.

Want to learn more about how Gyre Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Gyre Therapeutics, Inc. Stock Price: Bottom Line

As of June 3, 2026, Gyre Therapeutics, Inc.’s stock price is $5.640, which is up 1.44% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Gyre Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.